Dwight H Owen, MD, MS | Medical ...

Dr. Dwight Owen, MD

Claim this profile

Ohio State University Comprehensive Cancer Center

Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
13 reported clinical trials
19 drugs studied

Area of expertise

1Lung Cancer
Global Leader
Dwight Owen, MD has run 12 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
EGFR positive
Stage III
2Non-Small Cell Lung Cancer
Dwight Owen, MD has run 6 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage IV
EGFR positive
ALK

Affiliated Hospitals

Image of trial facility.
Ohio State University Comprehensive Cancer Center
Image of trial facility.
The Ohio State University Wexner Medical Center

Clinical Trials Dwight Owen, MD is currently running

Image of trial facility.

Vismodegib + Atezolizumab

for Lung Cancer

This phase Ib trial tests the safety, side effects, and best dose of the combination of vismodegib and atezolizumab in treating patients with non-small cell lung cancer (NSCLC) that has come back after a period of improvement (recurrent) or has spread from where it first started (primary site) to other places in the body (metastatic). Vismodegib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving a combination of vismodegib and atezolizumab may be safe, tolerable and/or effective than either drug alone in treating patients with recurrent or metastatic NSCLC.
Recruiting1 award Phase 16 criteria
Image of trial facility.

Temozolomide + Atezolizumab

for Small Cell Lung Cancer

This phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung cancer that has spread to other places in the body (metastatic) or has come back (recurrent). Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving temozolomide and atezolizumab as second or third line treatment may help prolong survival in patients with small cell lung cancer.
Recruiting1 award Phase 215 criteria

More about Dwight Owen, MD

Clinical Trial Related1 year of experience running clinical trials · Led 13 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Dwight Owen, MD has experience with
  • Atezolizumab
  • Pembrolizumab
  • Carboplatin
  • Vismodegib
  • Sunitinib Malate
  • Osimertinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Dwight Owen, MD specialize in?
Is Dwight Owen, MD currently recruiting for clinical trials?
Are there any treatments that Dwight Owen, MD has studied deeply?
What is the best way to schedule an appointment with Dwight Owen, MD?
What is the office address of Dwight Owen, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security